CRISPR Therapeutics AG saw its shares fall 6.75% on Tuesday after the company disclosed a proposed offering of convertible senior notes totaling $350 million. The gene-editing company said the planned issuance would be conducted in a private placement to qualified institutional buyers under Rule 144A of the Securities Act.
In its announcement, CRISPR Therapeutics said it expects to grant the initial purchasers an option to acquire up to an additional $52.5 million in aggregate principal amount of the notes. The firm described the securities as senior, unsecured obligations of the company.
The notes are scheduled to accrue interest and pay that interest semiannually in arrears on March 1 and September 1 of each year, with the first interest payment date beginning on September 1, 2026. Unless they are earlier converted, redeemed or repurchased, the notes will mature on March 1, 2031.
Upon conversion of the notes, CRISPR Therapeutics stated it will deliver common shares that have a nominal value of CHF 0.03 per share. The company also disclosed that the interest rate, the initial conversion rate and other terms of the notes will be determined at the time the offering is priced.
CRISPR Therapeutics indicated it intends to use the net proceeds from the offering for general corporate purposes. The company did not provide additional details about specific uses for the funds.
Context and next steps
The offering remains subject to completion of the private placement process and final pricing, at which point the concrete interest and conversion mechanics will be disclosed. Until pricing occurs, the stated commercial terms beyond timing and structure remain to be set.
Investors and market participants will watch for the final pricing and any further detail from CRISPR Therapeutics about how the company plans to allocate the net proceeds, as the company has not provided further specifics.